Literature DB >> 17343426

The Erice Manifesto: for global reform of the safety of medicines in patient care.

.   

Abstract

The science of pharmacovigilance--monitoring and evaluating drug safety issues and communicating them effectively--is a vital activity of worldwide significance in the safeguarding of patient welfare and public health. Its clinical, public health and economic importance has been demonstrated, but it needs to be better understood and appreciated by politicians, the media and the public. Pharmacovigilance is evolving from being a largely reactive discipline, concentrating on the discovery of harm caused by marketed drugs, to a proactive study of their safety, effectiveness and associated risk factors in normal medical practice and use by patients. The Erice Manifesto specifies the challenges which must be addressed to ensure the continuing development and usefulness of the science, in particular: The active involvement of patients and the public in the core debate about the risks and benefits of medicines, and in decisions about their own treatment and health . The development of new ways of collecting, analysing and communicating information about the safety and effectiveness of medicines; open discussion about it and the decisions which arise from it . The pursuit of learning from other disciplines about how phamacovigilance methods can be improved, alongside wide-ranging professional, official and public collaboration . The creation of purposeful, coordinated, worldwide support amongst politicians, officials, scientists, clinicians, patients and the general public, based on the demonstrable benefits of pharmacovigilance to public health and patient safety.

Entities:  

Mesh:

Year:  2007        PMID: 17343426     DOI: 10.2165/00002018-200730030-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  10 in total

1.  The future of pharmacovigilance: a personal view.

Authors:  I Ralph Edwards
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

2.  The good old drugs!

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  Tomorrow's world.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.

Authors:  Linda Härmark; Florence van Hunsel; Birgitta Grundmark
Journal:  Drug Saf       Date:  2015-04       Impact factor: 5.606

5.  Medication errors: pharmacovigilance centres in detection and prevention.

Authors:  Rachida Soulaymani Bencheikh; Ghita Benabdallah
Journal:  Br J Clin Pharmacol       Date:  2009-06       Impact factor: 4.335

Review 6.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

7.  Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers.

Authors:  Dustin D French; Curtis E Margo
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?

Authors:  Linda Härmark; June Raine; Hubert Leufkens; I Ralph Edwards; Ugo Moretti; Viola Macolic Sarinic; Agnes Kant
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

9.  A New Erice Report Considering the Safety of Medicines in the 21st Century.

Authors:  Ivor Ralph Edwards
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

10.  A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China.

Authors:  Ningsheng Wang; Yue Chen; Biqi Ren; Yufang Xiang; Nan Zhao; Xianyan Zhan; Bianling Feng
Journal:  BMC Health Serv Res       Date:  2022-03-08       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.